Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Roche NimbleGen has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

Drug monitoring may provide alternative treatments for patients with severe H1N1

An international team of Canadian and Spanish scientists have found the first potential immunological clue of why some people develop severe pneumonia when infected by the pandemic H1N1 virus.

16 Dec 2009

NREF supports new post-residency fellowship grant program

The NREF has reached an agreement with Codman & Shurtleff, Inc. to provide funding to the NREF in support of the Foundation's new post-residency fellowship grant program.

16 Dec 2009

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Hospira to acquire Orchid's pharmaceuticals business for $400 million

Hospira, Inc., the world leader in generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company and among the top-five generic beta-lactam antibiotics manufacturers globally, today announced an agreement for Hospira to acquire Orchid's generic injectable finished-dosage form pharmaceuticals business for approximately $400 million.

15 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

Magellan Health Services announces projected 2010 revenue and earnings growth

Magellan Health Services, Inc. today announced that, for 2010, it expects to generate net revenue in the range of $3.0 billion to $3.2 billion, net income in the range of $95.5 million to $115.0 million, and earnings per share in the range of $2.73 to $3.29 on a diluted basis.

15 Dec 2009

Senator Arlen Specter's amendment to The Patient Protection and Affordable Care Act applauded

More than twenty of our nation's premiere physician organizations applaud Senator Arlen Specter (D-PA) for introducing an amendment to The Patient Protection and Affordable Care Act (H.R. 3590).

15 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Cancer patients with dementia have lower survival rate than patients with cancer alone, says study

A new study published by researchers from the University of Georgia and the Moffitt Cancer Center in Tampa, Fla., has found that cancer patients with dementia have a dramatically lower survival rate than patients with cancer alone, even after controlling for factors such as age, tumor type and tumor stage.

15 Dec 2009

Alvogen establishes operations in Asia and opens an office in Shanghai

Alvogen, Inc. (Alvogen), the U.S.-based pharmaceutical company, today announced that it has established operations in Asia and has opened an office in Shanghai, China that will lead efforts to commercialize the company’s products in the country.

15 Dec 2009

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

15 Dec 2009

Oncology News and Research

Further Reading

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

Drug monitoring may provide alternative treatments for patients with severe H1N1

NREF supports new post-residency fellowship grant program

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Hospira to acquire Orchid's pharmaceuticals business for $400 million

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

Magellan Health Services announces projected 2010 revenue and earnings growth

Senator Arlen Specter's amendment to The Patient Protection and Affordable Care Act applauded

Pure populations of immature cells that enable male reproduction isolated and transplanted

Cancer patients with dementia have lower survival rate than patients with cancer alone, says study

Alvogen establishes operations in Asia and opens an office in Shanghai

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News